Ortho Clinical Diagnostics, Raritan, NJ (Ortho), and Sphingotec GmbH, Hennigsdorf, Germany, recently reached a long-term, global strategic agreement regarding the endothelial function marker, biologically active adrenomedullin (Sphingotest Bio-ADM), which measures patients’ rate of recovery from acute heart failure. The agreement permits Ortho to use the Sphingotest Bio-ADM immunoassay on Ortho’s automated Vitros immunodiagnostics and integrated systems for small-, mid-, and high-volume clinical laboratories.

Product availability is subject to local regulatory requirements.

Robert Yates, Ortho Clinical Diagnostics.

Robert Yates, Ortho Clinical Diagnostics.

“Ortho is committed to the continued expansion of our menu offerings, through both internal research and development programs and strategic collaborations,” says Robert Yates, chief operating officer at Ortho. “Our strategic agreement regarding the Sphingotest Bio-ADM assay positions us to bring this novel cardiac biomarker to a broad range of clinical labs around the world.”

Congestion in acute heart failure, which is mainly caused by endothelial dysfunction, is a serious medical problem and a main driver of rehospitalizations in these patients. Next to the wide use of natriuretic peptides mainly for the diagnosis of heart failure, accurate determination of residual congestion during and after treatment is a high unmet medical need to assess the adequacy of acute heart failure therapy.1–3 In particular, residual heart congestion at hospital discharge is associated with a high risk of rehospitalization and mortality, emphasizing the need for assessing and monitoring the adequacy of decongestion therapy throughout hospitalization.4


Andreas Bergmann, PhD, Sphingotec.

“Working with Ortho Clinical Diagnostics will help us deliver our standardized Sphingotest Bio-ADM assay to laboratories around the world to help them efficiently diagnose heart failure patients with residual congestion, in time for meaningful intervention, including a potential change in medication, to take place,” says Andreas Bergmann, founder and general manager of Sphingotec GmbH.

Sphingotest Bio-ADM is indicated for use as an aid in monitoring decongestion in patients hospitalized with acute heart failure.


  1. Parinello G, Greene SJ, Torres D, et al. Water and sodium in heart failure: a spotlight on congestion. Heart Fail Rev. 2015;20(1):13–24; doi: 10.1007/s10741-014-9438-7.
  1. Kremer D, Demissei BG, Rubio-Gracia J, et al. Bio-ADM: a novel marker of congestion in patients with acute heart failure [presentation abstract no. 878]. Paris: Presentation at the Heart Failure 2017 and World Congress on Acute Heart Failure, April 29–May 2, 2017. Eur J Heart Fail. 2017;19(5; Suppl. S1):197; doi: 10.1002/ejhf.2017.19.issue-S1/issuetoc.
  1. Costanzo MR, Jessup M. Treatment of congestion in heart failure with diuretics and extracorporeal therapies: effects on symptoms, renal function, and prognosis. Heart Fail Rev. 2012;17(2):313–324; doi: 10.1007/s10741-011-9248-0.
  1. Teichman SL, Maisel AS, and Storrow AB. Challenges in acute heart failure clinical management: optimizing care despite incomplete evidence and imperfect drugs. Crit Pathways in Cardiol. 2015;14(1):12–24; doi: 10.1097/HPC.0000000000000031.